Physician profile
Walter Evans
NPI 1871609388
$20,595.21
in general payments reported to CMS, 2019-2025
66 companies · $3,586 in 2025
The $3,586 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,576 · 2020: $2,306 · 2021: $3,194 · 2022: $3,138 · 2023: $2,750 · 2024: $3,046 · 2025: $3,586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,365 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,364.75 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,995.44 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $1,908.53 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Biogen, INC. | $1,547.50 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Emd Serono, INC. | $1,063.35 | 2019-2025 | Mavenclad |
| Genzyme Corporation | $950.16 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $946.75 | 2019-2025 | |
| Sk Life Science, INC. | $834.61 | 2020-2025 | |
| Eisai INC. | $827.95 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $724.11 | 2019-2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $619.10 | 2019-2025 | Ultomiris, Soliris |
| Abbvie INC. | $594.60 | 2021-2025 | |
| Pfizer INC. | $526.73 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $427.69 | 2019-2025 | Ingrezza |
| Lilly USA, LLC | $427.60 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Mallinckrodt Hospital Products INC. | $418.36 | 2020-2025 | Acthar |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $399.87 | 2021-2025 | Zeposia |
| Supernus Pharmaceuticals, INC. | $378.66 | 2019-2025 | Oxtellar Xr, Qelbree |
| Amgen INC. | $371.58 | 2019-2025 | Uplizna, Aimovig |
| Genentech USA, INC. | $309.26 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Lundbeck LLC | $295.73 | 2019-2025 | Vyepti, Rexulti |
| Jazz Pharmaceuticals INC. | $282.48 | 2019-2025 | Epidiolex |
| Acorda Therapeutics, INC | $271.30 | 2019-2023 | Inbrija |
| Argenx US, INC. | $268.53 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Janssen Pharmaceuticals, INC | $263.78 | 2020-2023 | Ponvory |
| Csl Behring | $250.33 | 2019-2024 | Hizentra |
| Horizon Therapeutics Plc | $242.92 | 2021-2023 | Uplizna |
| Mdd US Operations, LLC | $241.84 | 2019-2025 | Gocovri |
| Amneal Pharmaceuticals LLC | $236.34 | 2019-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Akcea Therapeutics, INC. | $231.08 | 2019-2021 | |
| Kyowa Kirin, INC. | $227.01 | 2020-2024 | Nourianz |
| Harmony Biosciences LLC | $194.45 | 2021-2025 | Wakix |
| Otsuka America Pharmaceutical, INC. | $184.79 | 2023-2025 | Rexulti, Nuedexta |
| Allergan, INC. | $183.17 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $157.10 | 2023-2025 | Fycompa |
| Takeda Pharmaceuticals U.S.A., INC. | $144.01 | 2023-2025 | Hyqvia, Gammagard |
| Alnylam Pharmaceuticals INC. | $140.53 | 2022-2025 | Onpattro, Amvuttra |
| Neurelis, INC. | $128.00 | 2023-2025 | Valtoco |
| Scilex Pharmaceuticals INC. | $117.56 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $111.94 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $89.08 | 2024-2025 | Wainua |
| Grifols USA, LLC | $84.52 | 2023-2025 | Gamunex-C, Xembify |
| Tg Therapeutics, INC. | $84.03 | 2024-2025 | |
| Upsher-Smith Laboratories LLC | $79.63 | 2020-2021 | |
| Amylyx Pharmaceuticals, INC. | $75.70 | 2023 | Relyvrio |
| Sumitomo Pharma America, INC. | $70.93 | 2023 | Aptiom |
| Mallinckrodt Enterprises LLC | $67.27 | 2019 | |
| Sanofi-Aventis U.S. LLC | $64.41 | 2020-2021 | |
| Axsome Therapeutics, INC. | $55.04 | 2024-2025 | Sunosi |
| Livanova USA, INC. | $50.42 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $49.59 | 2021 | |
| Tanabe Pharma America, INC. | $47.28 | 2019-2022 | |
| Banner Life Sciences, LLC | $44.88 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $41.45 | 2022 | |
| Zogenix INC. | $34.03 | 2021 | |
| Vanda Pharmaceuticals INC. | $26.94 | 2025 | Ponvory |
| Janssen Biotech, INC. | $24.06 | 2025 | |
| Arbor Pharmaceuticals, INC. | $21.47 | 2019 | |
| Aquestive Therapeutics, INC. | $20.21 | 2021 | |
| Bausch Health US, LLC | $18.53 | 2019 | |
| Merck Sharp & Dohme LLC | $17.96 | 2023 | Belsomra |
| Cala Health, INC. | $15.86 | 2023 | Cala Trio |
| Avadel Cns Pharmaceuticals, LLC | $15.27 | 2024 | Lumryz |
| Avion Pharmaceuticals | $14.94 | 2022 | |
| Alfasigma USA, INC. | $13.95 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.86 | 2021 | |
| Hologic Sales and Service, LLC | $10.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.